CBD and Treatment of Osteoarthritis in Dogs

07/21/2021 Author: Mirka 6 min read

CBD for Treating Osteoarthritis in Dogs

Long-term treatment of osteoarthritis with non-steroidal anti-inflammatory drugs, which are primarily used in veterinary practice to eliminate pain and inflammation, can have serious adverse effects on the digestive system and kidneys. This is especially problematic in elderly and polymorbid dogs.

Joint problems in dogs represent one of the most complex challenges faced by pet owners, especially when it comes to large breeds predisposed to osteoarthritis. This degenerative condition not only affects the quality of life of our pets but also raises important therapeutic dilemmas due to the side effects of traditional pharmacological treatments.

The search for safer therapeutic alternatives has directed scientific attention toward cannabinoid compounds, particularly CBD (cannabidiol), as a possible complement or alternative to conventional non-steroidal anti-inflammatory drugs (NSAIDs) in the management of canine osteoarthritis.

Risk Profile in Canine Breeds

Canine osteoarthritis presents a characteristic distribution that mainly affects molosser breeds and large breeds. Among the most susceptible are the Dogue de Bordeaux, Bullmastiff, Fila Brasileiro, Neapolitan and Spanish Mastiff, as well as the Pyrenean Mountain Dog. However, more common breeds such as the German Shepherd, Golden Retriever, and Labrador Retriever also show significant predisposition.

It is important to note that size is not the only determining factor. Small and medium breeds can also develop this pathology, which considerably broadens the spectrum of animals that could benefit from alternative cannabinoid-based therapies.

Scientific Research: Controlled Study with CBD

A placebo-controlled clinical study published in 2018 specifically evaluated the safety and analgesic efficacy of cannabidiol in dogs diagnosed with osteoarthritis. The research employed a rigorous protocol that included oral administration of CBD oil at doses of 2 mg/kg every twelve hours, compared with a placebo composed of olive, anise, and mint oils.

The researchers initially considered doses of 8 mg/kg, but factors of economic feasibility and practicality in dosing led to focusing on the lower dose, especially considering the implications for owners of large breeds.

Methodology and Inclusion Criteria

The inclusion criteria were strict and clinically relevant: radiographic confirmation of osteoarthritis, visual evidence of lameness, owner assessment of pain, and sensitivity detected through veterinary palpation. Each canine participant underwent a complete blood count prior to the start of treatment.

The protocol allowed the concurrent use of specifically authorized medications, including non-steroidal anti-inflammatory drugs (NSAIDs), fish oil, glucosamine, and chondroitin sulfate. However, discontinuation of analgesics such as gabapentin and tramadol was required two weeks in advance.

Characteristics of the Genetic Material Used

The study used industrial hemp as a source of extraction, which means the results are specific to extracts with high concentrations of CBD and minimal amounts of other cannabinoids and terpenes. This specificity is crucial for the interpretation of results, since different cannabis genetics can produce variable cannabinoid and terpene profiles.

The genetic diversity available in specialized seed collections demonstrates the chemical complexity of cannabis, where each variety presents a unique profile of active compounds that could influence the observed therapeutic effects.

Study Population and Preliminary Results

The research included a representative sample of 22 dogs, of which 16 completed the full protocol. Participants were categorized by breed, body weight, age, specific diagnosis, and concurrent NSAID use, providing a comprehensive framework for result analysis.

Among the documented cases, various presentations of osteoarthritis were included: from mild joint involvement to severe cases with multiple joint compromise, including elbows, knees, hips, and carpal joints.

Implications for Veterinary Medicine

The results of this pioneering research suggest that cannabinoids derived from specific cannabis genetics could represent a valuable therapeutic tool in the management of painful conditions in veterinary medicine.

Understanding terpene profiles and cannabinoid profiles becomes fundamental for optimizing therapeutic protocols. Each cannabis variety presents unique chemical characteristics that could translate into specific therapeutic benefits for different clinical presentations of canine osteoarthritis.

This scientific approach to the use of specialized cannabinoid genetic material opens new perspectives in the development of safer and more effective veterinary therapies, especially for cases where conventional treatments present significantathyroid limitations due to adverse effects or specific contraind Tudorii раза absintRepublican{]